Q4 2025

Filed Mar 12, 2026 · 10-K · 71 days after period end · 0001628280-26-017253

Q4 2025 · 10-K

derived · Computed from the longer spans the company filed.

Revenue

$6.00K

derived−45.5% vs Q4 2024

Net Income

-$140.72M

derivedN/M vs Q4 2024

EPS, diluted—

Same quarter

Metric	Q4 2025derived from reported figures	Q4 2024derived from reported figures	Q4 2023derived from reported figures	Q4 2022derived from reported figures
Revenue	$6.00K	$11.00K	$13.00K	$48.39M
Net Income	-$140.72M	-$191.94M	-$52.93M	-$8.40M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Lyell Immunopharma, Inc. · CIK 1806952 · Engraved from SEC EDGAR